HK1034912A1 - Novel fatty analogues for the treatment of obesity - Google Patents

Novel fatty analogues for the treatment of obesity

Info

Publication number
HK1034912A1
HK1034912A1 HK01105690A HK01105690A HK1034912A1 HK 1034912 A1 HK1034912 A1 HK 1034912A1 HK 01105690 A HK01105690 A HK 01105690A HK 01105690 A HK01105690 A HK 01105690A HK 1034912 A1 HK1034912 A1 HK 1034912A1
Authority
HK
Hong Kong
Prior art keywords
sub
treatment
obesity
novel fatty
analogues
Prior art date
Application number
HK01105690A
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica filed Critical Thia Medica
Publication of HK1034912A1 publication Critical patent/HK1034912A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HK01105690A 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of obesity HK1034912A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (1)

Publication Number Publication Date
HK1034912A1 true HK1034912A1 (en) 2001-11-09

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
HK01105684A HK1034909A1 (en) 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of diabetes
HK01105689A HK1034911A1 (en) 1998-05-08 2001-08-14 Novel fatty acid analogues for the treatment of secondary restenosis
HK01105690A HK1034912A1 (en) 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of obesity

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK01105684A HK1034909A1 (en) 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of diabetes
HK01105689A HK1034911A1 (en) 1998-05-08 2001-08-14 Novel fatty acid analogues for the treatment of secondary restenosis

Country Status (18)

Country Link
US (4) US6365628B1 (ja)
EP (5) EP1075259B1 (ja)
JP (3) JP5057003B2 (ja)
KR (3) KR100701503B1 (ja)
CN (3) CN1223343C (ja)
AT (5) ATE336239T1 (ja)
AU (4) AU7240398A (ja)
BR (2) BR9910296A (ja)
CA (3) CA2331395C (ja)
DE (5) DE69932864D1 (ja)
DK (3) DK1075259T3 (ja)
ES (3) ES2204142T3 (ja)
HK (3) HK1034909A1 (ja)
NO (3) NO20005463L (ja)
NZ (3) NZ508047A (ja)
PT (2) PT1075259E (ja)
RU (3) RU2219920C2 (ja)
WO (4) WO1999058120A1 (ja)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
WO2001037827A1 (en) * 1999-10-13 2001-05-31 Chacon Marco A Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DK1547614T3 (da) * 2002-05-28 2011-04-04 Ajinomoto Kk Medicinsk sammensætning til inhibering af ekspressionen af ATP-citrat-lyase og anvendelse deraf
JP5008258B2 (ja) 2002-06-20 2012-08-22 アイシー・ベック・リミテッド 含硫黄ホスホリピド誘導体
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
KR20050071565A (ko) * 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
US7705016B2 (en) 2003-02-13 2010-04-27 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
CN1934072A (zh) * 2004-01-30 2007-03-21 派普林生物脂股份有限公司 治疗和载体分子
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
CN1961213A (zh) * 2004-05-28 2007-05-09 詹森药业有限公司 新的在清醒大鼠中静脉给药和血液取样模型
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NZ553261A (en) * 2004-07-19 2010-12-24 Thia Medica As Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
BRPI0611159A2 (pt) * 2005-05-04 2012-07-31 Pronova Biopharma Norge As composto e respectivo processo e fabrico, composiÇÕes farmacÊutica e de Ácido graxo, usos de composto e mÉtodos de controle da reduÇço do peso corpàreo e/ou prevenÇço do ganho de peso corpàreo, de tratamento e/ou prevenÇço da obesidade ou de uma condiÇço de sobrepeso, do diabete, de doenÇas relacionadas com a amiloidose, de tratamento ou profilaxia de fatores méltiplos de risco para doenÇas cardiovasculares e de prevenÇço do derrame cerebral, de ataques isquÊmicos cerebrais ou passageiros relacionados com a aterosclerose de vÁrias artÉrias
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
EP2083817A4 (en) * 2006-10-20 2009-12-23 Cpd Llc METHOD FOR RECONSTRUCTING THE EFFECT OF INCRETIN
KR101544584B1 (ko) * 2006-11-01 2015-08-13 프로노바 바이오파마 너지 에이에스 오메가-3 지질 화합물
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2722114A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
MX366137B (es) 2009-05-08 2019-06-28 Pronova Biopharma Norge As Acidos grasos poliinsaturados para el tratamiento de trastornos relacionados a las areas de los trastornos cardiovasculares, metabolicos e inflamatorios.
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
JP2014505017A (ja) 2010-11-05 2014-02-27 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物を用いる処置方法
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
CA2904827C (en) 2013-03-11 2020-10-27 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
US10792266B2 (en) 2017-10-23 2020-10-06 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
EP3934639A4 (en) * 2019-03-04 2023-01-11 Epitracker, Inc. FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Also Published As

Publication number Publication date
KR100701502B1 (ko) 2007-04-02
CN1245157C (zh) 2006-03-15
CA2331393A1 (en) 1999-11-18
CA2331408C (en) 2008-10-21
CN1223343C (zh) 2005-10-19
WO1999058122A1 (en) 1999-11-18
EP1284139A1 (en) 2003-02-19
JP4465672B2 (ja) 2010-05-19
US6417232B1 (en) 2002-07-09
ATE334666T1 (de) 2006-08-15
CA2331395A1 (en) 1999-11-18
NO20005461L (no) 2001-01-08
DK1075259T3 (da) 2003-11-03
EP1285652B1 (en) 2006-08-16
JP5057003B2 (ja) 2012-10-24
KR100701503B1 (ko) 2007-04-02
ATE306916T1 (de) 2005-11-15
AU762790B2 (en) 2003-07-03
US6365628B1 (en) 2002-04-02
HK1034909A1 (en) 2001-11-09
DK1075258T3 (da) 2003-12-01
ES2204142T3 (es) 2004-04-16
KR20010043314A (ko) 2001-05-25
DE69932864D1 (de) 2006-09-28
NO333143B1 (no) 2013-03-18
JP2002514596A (ja) 2002-05-21
RU2219920C2 (ru) 2003-12-27
ES2207253T3 (es) 2004-05-16
DE69909775D1 (de) 2003-08-28
CA2331408A1 (en) 1999-11-18
CN1302204A (zh) 2001-07-04
KR20010043315A (ko) 2001-05-25
KR100822077B1 (ko) 2008-04-14
AU4936799A (en) 1999-11-29
RU2221558C2 (ru) 2004-01-20
ES2251218T3 (es) 2006-04-16
BR9910297A (pt) 2002-01-02
CN1300211A (zh) 2001-06-20
RU2223095C2 (ru) 2004-02-10
WO1999058120A1 (en) 1999-11-18
AU4936699A (en) 1999-11-29
AU5451799A (en) 1999-11-29
HK1034911A1 (en) 2001-11-09
DE69927805T2 (de) 2006-07-06
JP2002514594A (ja) 2002-05-21
CA2331395C (en) 2008-10-14
AU7240398A (en) 1999-11-29
DK1075260T3 (da) 2006-02-06
NO20005462L (no) 2001-01-08
ATE247464T1 (de) 2003-09-15
US6441036B1 (en) 2002-08-27
CN1300212A (zh) 2001-06-20
PT1075258E (pt) 2004-01-30
EP1285652A1 (en) 2003-02-26
NO20005461D0 (no) 2000-10-30
NZ508047A (en) 2003-05-30
DE69927805D1 (de) 2006-03-02
AU761355B2 (en) 2003-06-05
ATE245416T1 (de) 2003-08-15
NZ508046A (en) 2003-08-29
DE69932645D1 (de) 2006-09-14
JP2002514595A (ja) 2002-05-21
WO1999058121A1 (en) 1999-11-18
DE69910559T2 (de) 2004-06-17
NO20005462D0 (no) 2000-10-30
EP1075260B1 (en) 2005-10-19
ATE336239T1 (de) 2006-09-15
WO1999058123A2 (en) 1999-11-18
CA2331393C (en) 2009-08-11
WO1999058123A3 (en) 2000-03-09
AU762792B2 (en) 2003-07-03
PT1075259E (pt) 2003-12-31
NO20005463D0 (no) 2000-10-30
US7026356B2 (en) 2006-04-11
NZ508045A (en) 2003-08-29
EP1075258B1 (en) 2003-08-20
DE69910559D1 (de) 2003-09-25
EP1284139B1 (en) 2006-08-02
EP1075259A1 (en) 2001-02-14
CN1244323C (zh) 2006-03-08
EP1075258A1 (en) 2001-02-14
NO20005463L (no) 2001-01-08
KR20010043316A (ko) 2001-05-25
DE69909775T2 (de) 2004-06-03
EP1075260A2 (en) 2001-02-14
EP1075259B1 (en) 2003-07-23
US20020198259A1 (en) 2002-12-26
BR9910296A (pt) 2002-01-15

Similar Documents

Publication Publication Date Title
HK1034912A1 (en) Novel fatty analogues for the treatment of obesity
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
BG103485A (en) Ketobanzamides as calpain inhibitors
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
EP1532131A4 (en) COMPOUNDS OF THE MOTILID TYPE
HK1068332A1 (en) Pyrane derivatives as both ace-and nep-inhibitors
WO2002008161A3 (en) Polymerization inhibitor for vinyl-containing materials
PL354959A1 (en) Silicon compounds derived from ascorbic acid
IL138638A0 (en) Processes for preparing intermediates
GB9920959D0 (en) Novel process
GR3029590T3 (en) Crystalline, polymorphic form of (s,s,s)-n-(1- 2-carboxy-3-(n?2 -mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine
PL363923A1 (en) Chloromethylation of thiophene
YU70799A (sh) Derivati tiazofurina
WO2003004652A3 (en) Use of a tyrosine recombinase for genetic engineering

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110423